FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4301683752> ?p ?o ?g. }

• W4301683752 endingPage "41" @default.
• W4301683752 startingPage "233" @default.
• W4301683752 abstract "We aimed to evaluate low intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease (IHD).5499 men aged between 45 years and 69 years at high risk of IHD were recruited from 108 practices in the UK that belong to the Medical Research Council's General Practice Research Framework. Initially, warfarin or placebo was randomly allocated to 1427 men; 1013 of these men later moved to a factorial stage of the trial, retaining their warfarin or placebo warfarin allocation and adding randomly allocated active or placebo aspirin. Another 4072 men entered directly into the factorial stage making a total of 5085 men. The four factorial treatment groups were: active warfarin and active aspirin (WA, n = 1277), active warfarin and placebo aspirin (W, n = 1268), and placebo warfarin and active aspirin (A, n = 1268), and placebo warfarin and placebo aspirin (P, n = 1272). The primary end-point was all IHD defined as the sum of coronary death and fatal and non-fatal myocardial infarction (MI).The mean International Normalised Ratio (INR) of those on active warfarin was 1.47. The mean warfarin dose was 4.1 mg a day (range 0.5 mg-12.5 mg). There were 410 IHD events (142 fatal, 268 non-fatal). The main effect of warfarin (i.e., WA and W vs A and P) was a reduction in all IHD of 21% (95% CI 4-35, p = 0.02) chiefly due to a 39% reduction (15-57, p = 0.003) in fatal events so that warfarin reduced the death rate from all causes by 17% (1-30, p = 0.04). The main effect of aspirin (i.e., WA and A vs W and P) was a reduction in all IHD of 20% (1-35, p = 0.04) almost entirely due to a 32% reduction (12-48, p = 0.004) in non-fatal events. Absolute reductions in all IHD due to warfarin or aspirin were 2.6 and 2.3 per 1000 person years, respectively. WA reduced all IHD by 34% (11-51, p = 0.006) compared with P. WA increased haemorrhagic and fatal strokes. Ruptured aortic or dissecting aneurysms occurred in 15 of those who were or had been on warfarin compared with three of those who had not (p = 0.01).These results add to evidence that aspirin reduces non-fatal IHD. Warfarin reduced all IHD chiefly because of an effect on fatal events. Combined treatment with warfarin and aspirin is more effective in the reduction of IHD than either agent on its own." @default.
• W4301683752 created "2022-10-05" @default.
• W4301683752 date "1998-01-24" @default.
• W4301683752 modified "2023-10-03" @default.
• W4301683752 title "Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework." @default.
• W4301683752 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9457092" @default.
• W4301683752 hasPublicationYear "1998" @default.
• W4301683752 type Work @default.
• W4301683752 citedByCount "99" @default.
• W4301683752 countsByYear W43016837522013 @default.
• W4301683752 countsByYear W43016837522014 @default.
• W4301683752 countsByYear W43016837522015 @default.
• W4301683752 countsByYear W43016837522016 @default.
• W4301683752 countsByYear W43016837522017 @default.
• W4301683752 countsByYear W43016837522018 @default.
• W4301683752 countsByYear W43016837522019 @default.
• W4301683752 countsByYear W43016837522020 @default.
• W4301683752 countsByYear W43016837522021 @default.
• W4301683752 countsByYear W43016837522022 @default.
• W4301683752 countsByYear W43016837522023 @default.
• W4301683752 crossrefType "journal-article" @default.
• W4301683752 hasConcept C126322002 @default.
• W4301683752 hasConcept C141071460 @default.
• W4301683752 hasConcept C142724271 @default.
• W4301683752 hasConcept C168563851 @default.
• W4301683752 hasConcept C203092338 @default.
• W4301683752 hasConcept C204243189 @default.
• W4301683752 hasConcept C204787440 @default.
• W4301683752 hasConcept C27081682 @default.
• W4301683752 hasConcept C2776301958 @default.
• W4301683752 hasConcept C2777628954 @default.
• W4301683752 hasConcept C2779161974 @default.
• W4301683752 hasConcept C500558357 @default.
• W4301683752 hasConcept C71924100 @default.
• W4301683752 hasConceptScore W4301683752C126322002 @default.
• W4301683752 hasConceptScore W4301683752C141071460 @default.
• W4301683752 hasConceptScore W4301683752C142724271 @default.
• W4301683752 hasConceptScore W4301683752C168563851 @default.
• W4301683752 hasConceptScore W4301683752C203092338 @default.
• W4301683752 hasConceptScore W4301683752C204243189 @default.
• W4301683752 hasConceptScore W4301683752C204787440 @default.
• W4301683752 hasConceptScore W4301683752C27081682 @default.
• W4301683752 hasConceptScore W4301683752C2776301958 @default.
• W4301683752 hasConceptScore W4301683752C2777628954 @default.
• W4301683752 hasConceptScore W4301683752C2779161974 @default.
• W4301683752 hasConceptScore W4301683752C500558357 @default.
• W4301683752 hasConceptScore W4301683752C71924100 @default.
• W4301683752 hasIssue "9098" @default.
• W4301683752 hasLocation W43016837521 @default.
• W4301683752 hasOpenAccess W4301683752 @default.
• W4301683752 hasPrimaryLocation W43016837521 @default.
• W4301683752 hasRelatedWork W1983144487 @default.
• W4301683752 hasRelatedWork W2002269694 @default.
• W4301683752 hasRelatedWork W2058581900 @default.
• W4301683752 hasRelatedWork W2188507800 @default.
• W4301683752 hasRelatedWork W2354177966 @default.
• W4301683752 hasRelatedWork W2372447844 @default.
• W4301683752 hasRelatedWork W2391115443 @default.
• W4301683752 hasRelatedWork W2587299378 @default.
• W4301683752 hasRelatedWork W4300054151 @default.
• W4301683752 hasRelatedWork W98764081 @default.
• W4301683752 hasVolume "351" @default.
• W4301683752 isParatext "false" @default.
• W4301683752 isRetracted "false" @default.
• W4301683752 workType "article" @default.